- Home
- PEPG vs RNXT Comparison
PEPG vs RNXT Comparison
Compare PEPG & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- RNXT
- Stock Information
- Founded
- PEPG 2018
- RNXT 2012
- Country
- PEPG United States
- RNXT United States
- Employees
- PEPG N/A
- RNXT N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- RNXT Health Care
- Exchange
- PEPG Nasdaq
- RNXT Nasdaq
- Market Cap
- PEPG 45.9M
- RNXT 44.6M
- IPO Year
- PEPG 2022
- RNXT 2021
- Fundamental
- Price
- PEPG $2.56
- RNXT $1.21
- Analyst Decision
- PEPG Buy
- RNXT Strong Buy
- Analyst Count
- PEPG 4
- RNXT 2
- Target Price
- PEPG $7.25
- RNXT $7.50
- AVG Volume (30 Days)
- PEPG 633.9K
- RNXT 765.0K
- Earning Date
- PEPG 11-06-2025
- RNXT 11-12-2025
- Dividend Yield
- PEPG N/A
- RNXT N/A
- EPS Growth
- PEPG N/A
- RNXT N/A
- EPS
- PEPG N/A
- RNXT N/A
- Revenue
- PEPG N/A
- RNXT $662,000.00
- Revenue This Year
- PEPG N/A
- RNXT $2,895.35
- Revenue Next Year
- PEPG N/A
- RNXT $313.04
- P/E Ratio
- PEPG N/A
- RNXT N/A
- Revenue Growth
- PEPG N/A
- RNXT N/A
- 52 Week Low
- PEPG $0.88
- RNXT $0.75
- 52 Week High
- PEPG $9.94
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- PEPG 74.19
- RNXT 52.98
- Support Level
- PEPG $1.82
- RNXT $1.20
- Resistance Level
- PEPG $2.24
- RNXT $1.45
- Average True Range (ATR)
- PEPG 0.28
- RNXT 0.13
- MACD
- PEPG 0.09
- RNXT 0.01
- Stochastic Oscillator
- PEPG 97.64
- RNXT 41.51
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.